Table 2. Vaccine effectiveness against symptomatic PCR and rapid antigen test confirmed SARS-CoV-2 infection for full cohort, and stratified by previous infection, vaccine brand and variant of interest.

		N participants	Total person-time (days)	PCR-confirmed symptomatic SARS-CoV-2 infection	RAT- confirmed symptomatic SARS-CoV-2 infection	All symptomatic SARS-CoV-2 infections	Unadjusted HR	(95% CI)	Unadjusted VE	(95%CI)	Adjusted VE	(95%CI)
Overall study period	Two doses—any vaccine
	Total cohort	1561
	Unvaccinated	1300	112050	90	34	124
	≥14d from 2nd dose	1054	105080	52	15	67	0.56	(0.40; 0.80)	44	(20; 60)	58	(41; 70)
	Without Prior Infection
	Unvaccinated	437	36109	63	25	88
	≥14d from 2nd dose	357	37683	40	14	54	0.48	(0.32; 0.70)	52	(30; 68)	56	(35; 70)
	With Prior Infection
	Unvaccinated	863	75941	27	9	36
	≥14d from 2nd dose	697	67397	12	1	13	0.41	(0.20; 0.84)	59	(16; 80)	58	(11; 80)
	Two doses—BNT162b2 vaccine
	Total cohort	1470
	Unvaccinated	1300	112050	90	34	124
	≥14d from 2nd dose	732	72695	25	6	31	0.40	(0.26; 0.63)	60	(37; 74)	68	(51; 79)
	Without Prior Infection
	Unvaccinated	437	36109	63	25	88
	≥14d from 2nd dose	239	25763	22	6	28	0.37	(0.24; 0.60)	63	(40; 76)	63	(43; 77)
	Two doses—BBIBP-CorV vaccine
	Total cohort	1337
	Unvaccinated	1300	112050	90	34	124
	≥14d from 2nd dose	227	21136	18	6	24	0.87	(0.52; 1.45)	13	(-45; 48)	40	(1; 64)
	Without Prior Infection
	Unvaccinated	437	36109	63	25	88
	≥14d from 2nd dose	91	8977	15	5	20	0.74	(0.41; 1.33)	26	(-33; 59)	31	(-26; 62)
Delta period	Two doses—any vaccine
	Total cohort	1556
	Unvaccinated	1162	72917	67	25	92
	≥14d from 2nd dose	1068	96751	49	15	64	0.60	(0.41; 0.86)	40	(14; 59)	52	(30; 66)
	Without Prior Infection
	Unvaccinated	378	21896	45	19	64
	≥14d from 2nd dose	339	30932	36	12	48	0.53	(0.35; 0.80)	47	(20; 65)	52	(26; 69)
	With Prior Infection
	Unvaccinated	784	51021	22	6	28
	≥14d from 2nd dose	729	65819	13	3	16	0.49	(0.25; 0.98)	51	(2; 75)	47	(-10; 74)
	Two doses—BNT162b2 vaccine
	Total cohort	1371
	Unvaccinated	1162	72917	67	25	92
	≥14d from 2nd dose	733	64109	23	6	29	0.46	(0.28; 0.73)	54	(27; 72)	61	(38; 75)
	Without Prior Infection
	Unvaccinated	378	21896	45	19	64
	≥14d from 2nd dose	222	19615	19	5	24	0.46	(0.28; 0.77)	54	(23; 72)	55	(26; 73)
	Two doses—BBIBP-CorV vaccine
	Total cohort	1250
	Unvaccinated	1161	72906	67	25	92
	≥14d from 2nd dose	227	20221	18	6	24	0.88	(0.52; 1.5)	12	(-50; 48)	37	(-9; 63)
	Without Prior Infection
	Unvaccinated	378	21896	45	19	64
	≥14d from 2nd dose	91	8474	15	5	20	0.72	(0.39; 1.31)	28	(-31; 61)	34	(-23; 64)

* due to the small number of events, brand-specific VE in participants with previous infection could not be estimated